# o2h Ventures

> o2h Therapeutics and AI EIS Fund


## Posts

- [o2h Ventures Shortlisted for Growth Investor of the Year at the One Nucleus Awards 2026](https://o2hventures.com/news/o2h-ventures-shortlisted-for-growth-investor-of-the-year-at-the-one-nucleus-awards-2026): o2h Ventures is pleased to announce that it has been shortlisted for the Growth Investor of the Year category at the One Nucleus Awards 2026. The One Nucleus Awards recognise organisations contributing across the life sciences ecosystem, including research, investment, services and enabling support. The Growth Investor category highlights investors who help translate innovative science into developing companies. As a biotech-specialist fund manager, o2h Ventures has supported more than 35 portfolio companies working across oncology, depression, dermatology, fibrosis, infectious disease and anti-ageing, all focused on improving human health. Based in Cambridge, o2h Ventures works closely with founders from company creation […]
- [o2h Ventures Named Runner-Up for Best EIS Investment Manager — Specialist at the 2025 Growth Investor Awards](https://o2hventures.com/news/o2h-ventures-named-runner-up-for-best-eis-investment-manager-specialist-at-the-2025-growth-investor-awards): o2h Ventures is thrilled to announce that it has been recognised as Runner-Up in the Best EIS Investment Manager — Specialist category at the 2025 Growth Investor Awards, hosted by Intelligent Partnership. The award celebrates investment managers with a clear specialist focus and a track record of driving meaningful impact through the Enterprise Investment Scheme (EIS). It highlights those who use investment as a genuine force for good — creating both commercial success and positive societal outcomes. As a biotech-specialist tax-efficient fund manager, o2h Ventures continues to champion early-stage life science and health-tech innovation across the UK. We have now […]
- [o2h Ventures Participates in Oversubscribed Seed Round to Advance CamGene Therapeutics’ RNA-Based Medicines](https://o2hventures.com/news/o2h-ventures-makes-followon-investment-in-camgene-therapeutics): Cambridge, UK  CamGene Therapeutics, a pioneering biotech company developing RNA-based treatments for hearing loss, has successfully closed an oversubscribed seed funding round. The round was led by UKI2S and joined by Eos Advisory, Cambridge Enterprise Ventures, HexTwo, LongRiver Investments, Parkwalk Advisors, with o2h Ventures participating as an investor. Hearing loss affects over 1.5 billion people worldwide, with more than 430 million experiencing moderate-to-severe impairment. Current solutions such as hearing aids and cochlear implants manage symptoms but cannot restore natural hearing. CamGene is pioneering RNA-based therapeutics that target the underlying cellular dysfunction, offering the potential to halt progression and restore hearing […]
- [o2h Ventures Portfolio Update: Monument Therapeutics Reaches Landmark Milestone in Schizophrenia](https://o2hventures.com/news/monument-therapeutics-reaches-landmark-milestone-in-schizophrenia): Cambridge, UK, We are thrilled to share an important milestone from our portfolio company, Monument Therapeutics, who have partnered with the Foundation for the National Institutes of Health (FNIH) to launch a clinical trial of MT1988, a novel treatment for cognitive impairment in schizophrenia. Schizophrenia is one of the top 15 causes of disability worldwide, with symptoms ranging from hallucinations and delusions to severe cognitive impairment. Despite its impact, there are currently no effective treatments available for the cognitive symptoms, nor for individuals in the early “clinical high-risk” phase of the illness. Monument’s pioneering approach, which combines innovative drug development […]
- [o2h Ventures Recognised at EISA Impact Awards 2025 for Exonate’s Topical Eye-Drop for Diabetic Retinopathy](https://o2hventures.com/news/eisa-impact-award-2025-o2h-ventures-exonate): Cambridge, UK:  o2h Ventures is honoured to have been Highly Commended in the Impact Award category at the Enterprise Investment Scheme Association (EISA) Awards 2025, held at the House of Lords on 19 June. The commendation highlights o2h Ventures’ pivotal investment into Exonate, a Cambridge-based biotech company developing an innovative, non-invasive eye drop treatment for diabetic eye disease and wet age-related macular degeneration (AMD). The EISA Impact Award celebrates EIS/SEIS investments that deliver measurable benefits to society or the environment. Exonate’s breakthrough therapy has the potential to transform retinal disease treatment, offering millions of patients worldwide a safer, needle-free alternative […]
- [o2h Ventures Shortlisted for Two EISA Awards 2025: Impact and Ecosystem Champion](https://o2hventures.com/news/o2h-ventures-eisa-awards-2025-finalist-impact-ecosystem-champion): Cambridge, UK o2h Ventures is proud to announce its dual nomination as a finalist at the EISA Awards 2025, recognised for both the EISA Impact Award and Ecosystem Champion categories. These nominations reflect o2h Ventures’ commitment to investing in groundbreaking biotechs and fostering a robust early-stage investment ecosystem in the UK.   EISA Impact Award: Recognition for Exonate Investment The EISA Impact Award nomination highlights o2h Ventures’ investment in Exonate, a pioneering biotech company developing a first-in-class, non-invasive eye drop treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. The nomination reflects Exonate’s potential for delivering a […]
- [o2h Ventures Makes SEIS investment in Sansanima, A University of Sheffield Spinout Developing Alternatives to Animal Testing](https://o2hventures.com/news/o2h-ventures-seis-investment-sansanima): Cambridge, UK o2h Ventures is pleased to announce its latest tax-efficient SEIS investment into Sansanima, a University of Sheffield spinout developing new technology to reduce the need for animal testing in the production of vital medicines, including vaccines for tetanus and botulinum toxin-based products. Sansanima has created a breakthrough testing method using human cells, offering an ethical and more efficient alternative to traditional animal-based testing. This breakthrough comes as the US FDA announced plans to phase out animal testing requirements for new medicines, highlighting global demand for modern solutions. With patents secured across the US, EU, South Korea, and Japan, […]
- [o2h Ventures Shortlisted for ‘Seed VC of the Year’ at UKBAA Angel Investment Awards 2025](https://o2hventures.com/news/o2h-ventures-seed-vc-of-the-year-ukbaa-2025): Cambridge, UK:  o2h Ventures has been shortlisted as a finalist for the “Seed VC of the Year” at the UKBAA Angel Investment Awards 2025. This nomination highlights our dedication to fostering groundbreaking early-stage biotech innovations that are transforming the future of human health. As a specialist biotech fund manager based in Cambridge’s thriving life sciences hub, o2h Ventures is at the forefront of identifying and accelerating pioneering ventures in pure-play therapeutics, biotech enablers, and AI/ML-driven biotechnology With deep roots in the biotech ecosystem, o2h Ventures has built a unique flywheel model—combining capital investment with hands-on mentorship, team-building expertise, and commercialization […]
- [o2h Ventures Backs Enedra Therapeutics, Targeting Complex Cancers](https://o2hventures.com/news/o2h-ventures-invests-in-enedra-therapeutics-advancing-drug-discovery-programs-to-find-cures-in-advancing-cancer): Enedra Therapeutics, a London-based therapeutics company, has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers. The financing round was supported by KU Leuven’s venture capital arm (Centre for Drug Design and Discovery), o2h Ventures, and follow-on investor Cancer Research Horizons, all of which bring significant experience in target validation and drug discovery and development. Enedra Therapeutics is building its bioinformatics platform and enabling a portfolio of targets towards drug discovery, aiming to create personalised medicines that address the large unmet […]
- [o2h Ventures Makes a Follow-on Investment in Qkine, the Cambridge-based Specialist in Growth Factor Manufacturing](https://o2hventures.com/news/o2h-ventures-makes-a-follow-on-eis-investment-in-qkine): Cambridge, UK o2h Ventures has made a follow-on EIS investment in Qkine, a Cambridge University spinout and a specialist developer and manufacturer of proteins for stem cell, organoid, and regenerative medicine applications. This latest investment is from the o2h human health knowledge-intensive EIS fund.  Qkine is renowned for its expertise in the design and manufacture of complex growth factors, including members of the TGF-beta family, which are produced using animal-origin free manufacturing processes, ensuring exceptional biochemical purity and bioactivity. Having initially invested in Qkine in 2020 at the seed stage, o2h Ventures made a further investment in 2022. Since then, […]
- [Monument Tx Advances Schizophrenia Treatment with £850K Funding Round; o2h Ventures Makes Follow-On Investment](https://o2hventures.com/press-releases/monument-tx-advances-schizophrenia-treatment-with-o2h-ventures-makes-follow-on-eis-investment): Cambridge, UK,  Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used to fund its schizophrenia programme and drive the next stage of growth for the company. Schizophrenia affects approximately 20 million people worldwide. Cognitive impairment associated with schizophrenia (CIAS), a core symptom of the condition, impacts memory, attention, and executive function, significantly reducing patients’ quality of life. Despite its profound effect, there are currently no approved treatments for CIAS. Monument Therapeutics […]
- [o2h Ventures Investment Spotlight - Revolutionising Prostate Cancer Treatment](https://o2hventures.com/news/o2h-ventures-investment-spotlight-revolutionising-prostate-cancer-treatment): Prostate cancer is the most common form of cancer for men, particularly affecting those over the age of 50. It develops when the cells in the prostate gland grow uncontrollably. The statistics in the UK alone highlight the urgency to find innovative treatments: These figures underscore the urgent need for advanced research and differential treatments that extend and enhance the quality of life and where Stratosvir, one of o2h Ventures’ portfolio companies, is aiming to impact. Stratosvir is leading the way in viral immunotherapy for advanced cancer, including allowing intravenous delivery and making it possible to dose multiple times. The […]
- [o2h Ventures Makes an Investment in Atelerix, an Innovative Gel-Based Tech to Preserve Live Cells](https://o2hventures.com/news/o2h-ventures-invests-in-atelerix-a-comapny-transforming-delivery-of-biological-cell-delivery): Cambridge, UK o2h Ventures is pleased to announce investment in Atelerix, a Newcastle University spinout that is redefining how biosamples essential for drug discovery and pharmaceutical research are stored and transported. Biosamples such as cells, tissues, and viruses are critical for life-saving drug discovery. Preserving and transporting them safely is a constant challenge. Traditional cryopreservation methods, while widely used, can reduce cell viability by up to 50% post-thaw and require costly, specialised equipment. Additionally, some biological materials, such as complex cell-based models, tissues, and blood products, cannot be frozen at all. This limitation creates a tight, inflexible, and high-wastage supply […]
- [o2h Ventures Invests in Revolver Therapeutics Revolutionising Childhood Cancer Treatment](https://o2hventures.com/news/o2h-ventures-invests-in-revolver-therapeutics-revolutionising-childhood-cancer): Cambridge, UK  o2h Ventures is pleased to announce its latest investment in Revolver Therapeutics, a University of Bath spin-out company. The company aims to transform pediatric cancer treatment through various approaches targeting childhood glioma. Revolver Therapeutics is revolutionising cancer treatment by harnessing its ability to inhibit previously “undruggable” transcription factors. Transcription factors are proteins that help turn specific genes on or off by binding to nearby DNA in the cell nucleus and function as “master regulators” in cancer. The innovative TBS platform discovers peptides that functionally inhibit transcription factors inside cells to overcome the traditional hurdles faced by small molecules […]
- [o2h Ventures Wins Best EIS Investment Manager - Specialist at Growth Investor Awards 2024](https://o2hventures.com/news/o2h-ventures-wins-best-eis-investment-manager): Cambridge, UK We are thrilled to announce that o2h Ventures has been recognised as the Best EIS Investment Manager — Specialist at the 10th annual Growth Investor Awards. Hosted by Intelligent Partnership, this year’s Growth Investor Awards mark a decade of celebrating UK SME investment opportunities. These awards shine a spotlight on companies and individuals who go above and beyond to support the UK’s burgeoning businesses, fostering job creation, driving economic growth, and championing innovation. The Best EIS Manager-Specialist category recognises investment managers specialising in Enterprise Investment Schemes (EIS) with a particular focus area on impactful underlying investments. The judging […]
- [o2h Ventures Portfolio Company ViaNautis Enters Strategic Collaboration Agreement with Eli Lilly to Accelerate Genetic Medicine Development](https://o2hventures.com/news/o2h-ventures-portfolio-company-vianautis-collaborates-with-eli-lilly): Cambridge, UK: ViaNautis Bio (“ViaNautis), a groundbreaking biotechnology company at the forefront of delivering targeted genetic nanomedicines and an o2h Ventures portfolio company, announced a strategic collaboration with Eli Lilly and Company (“Lilly”) to advance the development of genetic nanomedicines. This collaboration marks a pivotal milestone for ViaNautis in advancing its proprietary polyNaut® platform to offer groundbreaking solutions for patients with critical unmet needs. In November 2023, ViaNautis secured a $25 million Series A financing round, with Eli Lilly participating as an investor. ViaNautis’ proprietary polyNaut® nanovesicle platform uses advanced polymer materials and machine learning targeting tissues, enabling the potential […]
- [o2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024](https://o2hventures.com/news/o2h-ventures-finalist-in-the-best-eis-manager-at-the-growth-investor-awards-2024): Cambridge, UK We are pleased to share that for the third consecutive year, o2h Ventures has been qualified as a finalist in the Best EIS Manager—Specialist category at the Growth Investor Awards. Last year, we were recognized as runner-up in the same category.  This year’s Growth Investor Awards, hosted by Intelligent Partnership, mark a decade of celebrating UK SME investment opportunities. Over the years, the awards have honoured companies and individuals who go above and beyond to support the UK’s burgeoning businesses, fostering job creation, driving economic growth, and championing innovation. The Best EIS Manager – Specialist category acknowledges and […]
- [Proud Partner of the 30th Anniversary Event by EISA, celebrating three decades of Enterprise Investment Schemes (EIS)](https://o2hventures.com/news/o2h-ventures-partners-with-eisa-for-eis-celebration): The Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS) are government schemes that encourage investment into early-stage startups through a range of tax reliefs for investors in high-risk businesses. The EIS and the SEIS are responsible for £32 billion of investment into more than 56,000 UK startups. They are the leading schemes of their kind globally and play a fundamental role in attracting talent to the UK. The schemes ensure startups have access to crucial investment, driving innovation, creating jobs and fuelling growth across the whole of the UK. The EIS Association is the trade body for the […]
- [From Biotech Chemist to Family Office to Biotech Pioneer - Sunil Shah's Exciting Journey in Biotech](https://o2hventures.com/news/from-biotech-chemist-to-eis-funds-to-biotech-pioneer): Sunil Shah, CEO of o2h Ventures and Co-Founder of o2h Group, has had an inspiring and exciting journey in the biotech community for over two decades. In this exclusive interview, Sunil highlights his career journey and shares his outlook for the UK biotech sector with the Life Science Nation. Early Days and the Transition Sunil began his career as a consultant in the life science sector, which provided a strong foundation for his entrepreneurial journey. He and his brother co-founded two companies, including Oxygen Healthcare, which was sold eventually. Their success led them to identify market opportunities which led them […]
- [o2h Ventures Proud to be Shortlisted for the EISA Impact Award for a Second Year Running!](https://o2hventures.com/news/o2h-ventures-eis-assocaition-finalist-2024): o2h Ventures has been shortlisted for the EISA Impact Award for the second consecutive year. This nomination showcases the significant impact we are making within the early-stage biotech industry through our investments in the Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS). At o2h Ventures, we have a strong pipeline of 30+ innovative and exciting early-stage biotechs focusing on novel drug therapeutics and AI/ML enablers. These companies are focused on addressing critical and unmet health needs, including fatal diseases such as cancer and idiopathic pulmonary fibrosis (IPF), mental health conditions like depression, crucial diseases affecting the ear and […]
- [o2h Ventures Announces Seed Investment in AscendBio, A Company Advancing Therapies for Metabolic and Respiratory Diseases](https://o2hventures.com/news/o2h-ventures-announces-seed-eis-investment-in-ascendbio): Cambridge, UK o2h Ventures is pleased to announce its recent seed eis investment in AscendBio, a company dedicated to pioneering synthetic biology solutions for combatting life threatening metabolic and respiratory diseases. AscendBio is developing a revolutionary integrated cell programming platform to generate therapeutic cell types with unprecedented function and scalability for treating diseases. This innovative platform integrates design, engineering, and manufacturing processes, unlocking novel therapeutic possibilities and has been validated by producing therapeutic-grade liver cells with superior performance. They aim to fully exploit this integrated programming platform to develop multiple curative cell therapies across major therapeutic areas such as metabolic […]
- [o2h Ventures Invests in Vesynta, a Company Developing an AI Software to Maximise Therapeutic Potential and De-risk drug development](https://o2hventures.com/news/seis-investment-vesynta-an-ai-software-to-maximise-therapeutic-potential): Cambridge, UK o2h Ventures is pleased to announce another strategic SEIS investment in Vesynta. Vesynta is revolutionising precision drug dosing by integrating drug monitoring services with quantitative pharmacology to ensure better regimen safety and efficacy.  Vesynta overcomes the limitations of the “one size fits all” approach prevalent in drug label formation, which overlooks the unique ways different patients process drugs, leading to reduced quality of life, increased care costs, and sub-optimal drug development. 1st-generation solutions lack integration, scalability, and speed, limiting access to clinical insight and data quality. The result is a broken feedback loop and “trial and error” dose […]
- [o2h Ventures invests in ClotProtect, a Company Developing Treatment to Improve Bleeding and Survival Outcomes](https://o2hventures.com/news/seis-investment-in-clotprotect-therapeutics): Cambridge, UK o2h Ventures is pleased to announce an SEIS investment into ClotProtect Therapeutics, a company working towards developing a small molecule to improve efficacy and therefore bleeding and survival outcomes compared to existing treatments. Each year, approximately 1.5 million lives are lost due to haemorrhage and traumatic injuries[1]. Tranexamic acid (TXA) is currently used to manage bleeding and is recommended to be administered as soon as possible in bleeding patients with major trauma, patients at risk of losing 500ml and in all adults having major surgery. However, limitations of TXA exist, such as TXA only improves mortality in 30% […]
- [o2h Ventures Invests in Stratosvir - Advancing Viral Immunotherapy For Late-Stage Cancer](https://o2hventures.com/news/o2h-ventures-invests-in-stratosvir-advancing-viral-immunotherapy-for-late-stage-cancer): Cambridge, UK  o2h Ventures is pleased to announce its recent investment from the o2h human health SEIS fund into Stratosvir, a company focusing on viral immunotherapy solutions for late-stage cancer. The World Health Organisation (WHO) projects over 35 million new cancer cases by 2050, a staggering 77% increase from the estimated 20 million cases in 2022. Viral Immunotherapy can be a promising solution. It utilises viruses to target and replicate within tumour cells causing them to break down and die. The process also activates the immune system, helping it to identify and overcome immunosuppression caused by tumour cells. The oncolytic […]
- [o2h Ventures Announces SEIS Investment in Innovative mRNA-Based Hearing Loss Treatment Company, CamGene Therapeutics](https://o2hventures.com/news/o2h-ventures-announces-seis-investment-in-innovative-mrna-based-hearing-loss-treatment-company-camgene-tx): Cambridge, UK – o2h Ventures is pleased to announce its seed investment in Camgene Therapeutics, a pioneering mRNA medicine company focused on developing cutting-edge treatments for hearing loss. The World Health Organization (WHO) estimates that approximately 700 million people, or one in every ten individuals, will suffer from disabling hearing loss by the year 2050. The need for effective treatments is more pressing than ever. Current innovations, such as hearing aids and cochlear implants, offer limited enhancement, leaving a significant gap in healthcare solutions. The success of mRNA technology in the rapid development and production of COVID-19 vaccines, has paved […]
- [Pioneering innovation in biotech investments via o2h Ventures' human health S/EIS funds](https://o2hventures.com/news/o2h-ventures-pioneering-innovation-in-biotech-investments-with-eis-funds): o2h Ventures is pleased to bring you insights into the areas and stages of biotech investments from our funds, along with an overview of the overall performance achieved to date. So far, we have invested >$10M into >30 biotechs, many of which were in the early stages and have now progressed further. The main focus of our KI EIS fund in the next investments is being directed towards those companies that are further along the investment path, say 3+ years in, and thus potentially have a 5-year window to exit. As you will see below, we have invested in diseases of […]
- [Fuelling academic innovation and fostering entrepreneurship](https://o2hventures.com/news/fuelling-academic-innovation-and-investing-in-university-spinouts): The original publication of this blog can be found on the Intelligent Partnership website. To read the full blog, please visit: o2h ventures (ceros.com) The UK’s pursuit of becoming a scientific-superpower hinges on bolstering its knowledge centres to drive research, development and innovation. Universities serve as hubs for innovation, intellectual property generation and the commercialisation of research findings. University spinouts play a crucial role in creating a thriving innovation ecosystem, drawing from all academic institutions and disciplines. The life sciences sector is gaining prominence, witnessing a surge in equity deals within spinouts during the latter half of 2022 and into […]
- [o2h Ventures ‘WINS’ Runner Up for ‘Best EIS Manager - Specialist' at Growth Investor Awards 2023](https://o2hventures.com/press-releases/o2h-ventures-wins-runner-up-for-best-eis-manager-specialist-at-growth-investor-awards-2023): o2h Ventures is excited to announce its achievement as the Runner-Up at the prestigious and highly competitive Growth Investor Awards 2023 in the Best EIS Manager – Specialist category. The category acknowledges and celebrates outstanding investment managers in the Enterprise Investment Scheme (EIS) with a specialist focus on a particular area of underlying investments. The evaluation was based on assessing the success across business performance, investment inflows, impact on investors, adviser relations, and overall impact. o2h Ventures deeply believe in the immense potential of the UK biotech sector and its pivotal role in making Britain a scientific Superpower by 2023. […]
- [ViaNautis (formerly Somaserve) secured a $25M Series A round with a follow-on investment from o2h Ventures.](https://o2hventures.com/press-releases/vianautis-formerly-somaserve-secured-a-25m-series-a-round-with-a-follow-on-investment-from-o2h-ventures): Cambridge, UK: ViaNautis, (formerly Somaserve) has successfully raised a $25 million Series A funding round. The funding round was led by 4BIO Capital, BGF and UCB Ventures with the additional participation of the Cystic Fibrosis Foundation, Eli Lilly and Company. Existing investors also participated in the round including Origin Capital, Meltwind and o2h Ventures.  The acquired funds will be utilized for the development of the groundbreaking platform PolyNaut, in addition to the management and scientific team and advanced laboratory spaces. The company has developed a proprietary technology that represents a significant leap forward in the development of genetic medicines, particularly […]
- [o2h Ventures - Embracing autumn with exciting updates and amazing achievements!](https://o2hventures.com/news/o2h-ventures-autumn-newsletter-with-some-portfolio): Whilst Jeremy Hunt says he has no leeway to cut UK taxes at present, we at o2h Ventures are seeing a surge in investment opportunities from early-stage UK biotech. It feels like we are at the beginning of the next investment cycle and given the overall investment appetite and our growing presence; we have a large number of investment options coupled with more realistic valuations. We are thrilled to announce the launch of our latest investment opportunity, the Knowledge-intensive EIS Fund VI which is open for investment till 31st October 2023, and we believe this is the perfect time for […]
- [o2h Ventures continues to back Pencil Biosciences in its £5.6M Seed investment](https://o2hventures.com/news/o2h-ventures-continues-to-back-pencil-biosciences-in-its-5-6m-seed-investment): Cambridge, UK: Pencil Biosciences, an innovative gene editing and modulation technology company has successfully raised £5.6 million in seed funding; a company that o2h Ventures backed in its first PreSeed funding round.  Pencil Biosciences is developing a fully synthetic gene modulation and editing platform that will have impact across a wide range of applications, including new therapeutic options for patients with rare diseases and cancer. New investors include Octopus Investments, Northern Gritstone, Martlet Capital and SyndicateRoom. Existing investors – including UKi2S, the Greater Manchester and Cheshire Life Science Fund managed by Catapult Ventures, Jonathan Milner (Meltwind), o2h Ventures, also participated […]
- [Powering Regional Growth: the Cambridge Cluster](https://o2hventures.com/blog/powering-regional-growth-the-cambridge-cluster): The original publication of this blog can be found on the Intelligent Partnership website. To read the full blog, please visit: o2h ventures (ceros.com)  Our burgeoning life sciences sector contributes £94 billion to the UK’s economy each year and employs over 280,000 people. But did you know that Cambridge as a region is home to one of the world’s most successful life sciences and biotechnology hubs? Otherwise known as the ‘Cambridge Cluster’, the region has evolved over time into a global hub for innovation that is recognised today to be on par with other world-leading biotech clusters, such as Boston […]
- [o2h Ventures qualified as a finalist as Best EIS Manager - Specialist at Growth Investor Awards 2023](https://o2hventures.com/news/o2h-ventures-qualified-as-a-finalist-as-best-eis-manager-specialist-at-growth-investor-awards-2023): Cambridge, UK:  o2h Ventures is thrilled to announce that we have been recognized as a finalist at the Growth Investor Awards 2023 for the ‘Best EIS Manager – Specialist’ category for the second consecutive year. The category acknowledges and celebrates outstanding investment managers in EIS (Enterprise Investment Schemes) with a specialist focus on a particular area of underlying investments. The evaluation was based on assessing the success across business performance, investment inflows, impact on investors, adviser relations, customer feedback, and overall impact. As a leading biotech specialist tax-efficient fund manager, we are dedicated to supporting and nurturing early-stage biotech companies […]
- [June23 updates - o2h Ventures award finalists, portfolio company news and more...](https://o2hventures.com/blog/updates-on-o2h-seis-funds): It has been an exciting start to the summer, as we have seen o2h Ventures shortlisted for two awards this year. Firstly, the UKBAA award for “Best Seed VC of the Year’ and secondly, the EISA award for ‘Impact Investing’. It’s great to have some recognition for the efforts we put into both selecting our investments and supporting them. o2h Ventures has made 30 investments since inception and is either the first investor or lead investor in ~50% of these deals. As Turbine closed their ‘€20M’ Series A investment last quarter, we are seeing other companies from our portfolio to closing similar size […]
- [o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023](https://o2hventures.com/news/o2h-ventures-selected-as-finalist-for-best-seed-vc-in-ukbaa-awards-2023): Cambridge, UK: o2h Ventures, a leading venture capital firm focused on seed stage investing into biotech therapeutics in the UK, is delighted to announce that it has been selected as a finalist for “Best Seed VC of the Year” by the prestigious UKBAA Angel Investment Awards 2023. o2h Ventures is an early-stage biotech therapeutics fund that has seen many of its portfolio companies move into Series A and B investments, with three now moving through pivotal clinical studies in humans. We invests across the whole of the UK though 75% of its portfolio is based in Cambridge, UK. The team […]
- [o2h Ventures recognized as a finalist for the EISA Impact Award for 2023](https://o2hventures.com/news/o2h-ventures-recognized-as-a-finalist-for-the-eisa-impact-award-for-2023): London, UK, 07 June 2023: We are glad to announce that o2h Ventures has been nominated for EISA Awards as a finalist for the fourth time. Previously, we were finalists for Best Newcomer two years in a row (2020 & 2021) and in 2019, we were a finalist for an Outstanding Example Impactful EIS Investing. This time, we are honoured to be selected as a finalist in the esteemed EISA Impact Award category. We at o2h Ventures have strongly believed in the power of life sciences innovation to improve human health and also contribute to the UK economy. Our focus […]
- [PharmEnable raises $7.5M in Pre-Series A funding round with a follow-on investment from o2h Ventures](https://o2hventures.com/news/pharmenable-raises-7-5m-in-pre-series-a-funding-round-with-a-follow-on-investment-from-o2h-ventures): Cambridge, UK: o2h Ventures is thrilled to announce a follow-on investment in PharmEnable, a Cambridge-based, female-lead biotech company that specializes in drug discovery with a focus on chemical novelty, diversity, and complexity. PharmEnable is revolutionizing treatments available for cancer and neurological diseases by designing the next generation of small-molecule drugs.  During the recent funding round, PharmEnable successfully closed a total of $7.5 million in pre-Series A funding, which was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi Tanabe Pharma Group. The other esteemed participating investors include Cambridge Enterprise and Martlet Capital, among others. These funds will […]
- [Is Investing in SEIS ventures risky? - Join the o2h Chaitime Webinar](https://o2hventures.com/news/is-investing-in-seis-ventures-risky-join-the-o2h-chaitime-webinar): We are thrilled to be back with another season of our most celebrated series, the o2h Chaitime webinars, on 12th May 2023, Friday at 12:00 pm GMT.  Given the recent changes in SEIS legislation, there is a renewed interest in investing in SEIS-eligible businesses. However, in these investments, you are the first to put money in, how risky is this? We are thrilled to bring back our o2h ChaiTime series to discuss the risks of investing in these types of businesses and mitigation strategies through a discussion with a panel of SEIS fund managers and SEIS-backed CEOs.  We bring you […]
- [Tay Therapeutics, an o2h Ventures portfolio company secures a licensing deal worth over $65 million](https://o2hventures.com/news/tay-therapeutics-an-o2h-ventures-portfolio-company-secures-a-licensing-deal-worth-over-65-million): Cambridge, UK, 04 May 2023: Tay Therapeutics, a University of Dundee spin-out, has achieved a significant milestone by securing its second licensing deal with Vyne Therapeutics. The agreement could potentially generate over $65 million in milestone revenues for the first indications and up to 10% of net annual sales in tiered royalty payments. Tay Therapeutics is committed to developing small-molecule drugs for anti-inflammatory and orphan indications, aiming to discover first-in-class medicines that make a real difference to patients. Their licensed oral Bromodomain and Extra-Terminal motif (BET) inhibitor has shown potential in treating immuno-inflammatory and fibrotic disorders. o2h Ventures is proud […]
- [Longevity investment: ‘Good companies will continue to get funded’](https://o2hventures.com/blog/longevity-investment-good-companies-will-continue-to-get-funded): British antiaging biotech startup Five Alarm Bio (FAB) recently closed a seed funding round from investors including Cambridge Angels, Meltwind, o2h Ventures and SyndicateRoom, among others. The funding follows a $450,000 Biomedical Catalyst grant from Innovate UK, awarded to FAB early last year to develop its technology as a treatment for chronic wounds. Based on breakthrough advances made by its founder Dr William Bains in understanding of how age-associated chemical damage accumulates in cells and tissues, FAB is developing a small molecule approach aimed at boosting our defences as we age, to ultimately extend the healthy lifespan of our bodies. A key player […]
- [o2h Ventures deals pipeline, Knowledge-intensive EIS Fund closing on 5th April 2023](https://o2hventures.com/news/o2h-ventures-fund-open-till-the-5th-april-2023-hmrc-approved-ki-eis-human-health-fund): We are nearing the close of another round of successful investment in the o2h human health Funds. The table below shows investments that you could be investing into over the coming months. The final date to receive cleared funds is the 5th April 2023 for the Knowledge-intensive Human Health EIS fund. Below is the selection of opportunities – Metrion Biotech – Services Metrion is a specialist ion channel contract research organisation (CRO), based in Granta Park, Cambridge, UK. The Company provides a wide range of ion channel assay services to the worldwide pharmaceutical and bioscience industry. Ion channels are a […]
- [o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science](https://o2hventures.com/press-releases/o2h-ventures-makes-a-seis-investment-into-five-alarm-bio): o2h Ventures is delighted to announce a SEIS investment into Five Alarm Bio, a drug discovery company based in Cambridge, UK, that focuses on novel approaches to anti-aging with a broad potential for therapeutic application. FAB completed its seed investment round, raising over £500K to further its research to test new compounds. Prior to this, FAB received an Innovate UK grant of £360K in 2022 to initiate and support their research work. Five Alarm Bio (FAB) is developing drug candidates that boost our ability to minimize the effects of aging in humans. Anti-aging science is becoming more relevant than ever. […]
- [Early-Stage Biotech Investing in the UK through the lens of o2h Ventures](https://o2hventures.com/blog/early-stage-biotech-investing-in-the-uk-through-the-lens-of-o2h-ventures): The global biotech industry has an extraordinarily impact on science, healthcare, environment and the business. The British biotech industry has been under the spotlight during the COVID19 era highlighting the need for a homegrown vertically integrated biotechnology machine that designs, develops and manufactures new therapeutics. The UK, in our opinion, has emerged as a global leader in biotech innovation during the pandemic as it was instrumental in developing the first vaccine for COVID19 overcoming scientific, regulatory and manufacturing hurdles. The British government has also been supporting the biotech sector highlighting its significance in ‘Growing the bioeconomy: a national strategy to […]
- [Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD](https://o2hventures.com/press-releases/exciting-news-as-o2h-ventures-portfolio-company-small-pharma-unveils-positive-top-line-results-of-their-phase-iia-clinical-trial-for-treating-mdd): London, UK: Small Pharma, a biotechnology company listed on the TSXV: DMT and the OTCQB: DMTTF, and a portfolio company of o2h Ventures, announces positive results from its Phase IIa clinical trial of SPL026 with supportive therapy for the treatment of Major Depressive Disorder (MDD). Small Pharma is committed to developing short-duration psychedelic-assisted therapies for mental health conditions. The recent announcement of positive results from its Phase IIa clinical trial of SPL026 is a significant step forward in achieving this goal.  This was the first placebo-controlled trial of its sort, and the findings revealed that two weeks after taking SPL026 […]
- [o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs](https://o2hventures.com/press-releases/o2h-ventures-backed-kuano-wins-innovate-uk-funding-for-designing-the-next-generation-of-cancer-drugs): Cambridge UK: A grant from Innovate UK was awarded to Kuano, an o2h Ventures portfolio company for designing the next generation of cancer drugs.  Kuano is a discovery platform that combines target quantum mapping and AI led chemistry to enable faster development of drug candidates. Innovate UK is a government body that provides financial support to researchers, businesses, and innovators for their ground-breaking or radical products, services, discoveries, etc. through various competitions and challenges.  Kuano won funding from the highly competitive Biomedical Catalyst 2022 Round 1: industry-led R&D for their project worth half a million pounds towards the streamlined and […]
- [o2h Ventures invests in Qkine - once again…](https://o2hventures.com/press-releases/o2h-ventures-invests-in-qkine-once-again): Cambridge, UK: Qkine, an o2h Ventures portfolio company that produces high purity, animal free-growth factors, cytokines, and other complex proteins, closed its oversubscribed funding round at £4.3 million. The investors included o2h Ventures, Parkwalk , Downing, and Cambridge Angels. Qkine combines proprietary protein production process development with protein engineering techniques to develop unique and exceptionally high-purity products that tackle fundamental biological and scale-up challenges for the fast-growing stem cell, organoid, regenerative medicine, and cellular agriculture sectors. The funding round will enable the company to expand its research work with the new state of the art facility in Cambridge.  Additionally, it […]
- [o2h Ventures backed Turbine raises €20 Million](https://o2hventures.com/press-releases/o2h-ventures-backed-turbine-raises-e20-million): Cambridge, UK: o2h Ventures’ portfolio companies. Turbine, which is building a platform for simulating cell behaviour to understand cancer biology, concluded its Series A investment round after raising €20 million. It was led by Mercia and MSD Global Health Innovation fund with other investors including Day One Capital j. Pre-existing investors o2h Ventures, Accel, Delin Ventures, and XTX Ventures also participated or plan to participate in the round.  Turbine is developing its Simulated Cell platform to enhance the drug discovery and development process, resulting in a higher chance of success at all stages. The company was bootstrapped by the founders […]
- [Alevin Therapeutics won the Best Biotech Start-up at the OBN Awards 2022](https://o2hventures.com/press-releases/o2h-ventures-backed-company-won-the-best-biotech-startup-at-the-obn-awards-2022): London, UK: We are extremely delighted to announce that o2h Ventures backed Alevin Therapeutics, a University of Nottingham spinout, won the Best Biotech Startup Company award at the renowned OBN Awards 2022. Alevin Therapeutics is developing a platform of novel small molecule RGD integrin inhibitors having broad therapeutic applications in areas of high unmet clinical need – fibrosis, kidney disease, and cancer – with the most advanced asset being an inhaled drug for the treatment of lung fibrosis. For more information, please visit: https://obn.glueup.com/event/obn-awards-2022-52570/2022-winners—finalists.html   Media Contact: Juhi Shah Marketing Manager juhi.shah@o2h.com
- [Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events](https://o2hventures.com/news/oct-2022-o2h-ventures-fund-newsletter-ki-eis-closing-eisa-events): Firstly, welcome Rishi, whatever you and I think of his politics and experience, as an Anglo-Indian growing up in Cambridge in the 70’s and 80s, it is unbelievable that today we have an Anglo-Indian Prime Minister in the United Kingdom. His presence seems to be bringing calm to the markets. It is safe to assume that we are in a period of higher taxes to balance the books that we were under the leadership of Liz Truss. Knowledge Intensive Fund Fully Invested We have planned investments that will close in the 2-4 few weeks into: Kuano: Kuano is an artificial […]
- [Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates](https://o2hventures.com/news/invest-in-eis-investment-fund-by-o2h-ventures): Mini Budget – A Nice surprise! Whilst the mini budget from our new Chancellor Kwasi Kwatereng certainly was not mini from the headline grabbing point of view, there were some absolute gems in there for SEIS and EIS investors.   For EIS and SEIS investors, the Chancellor provided certainty that the schemes would extend beyond the sunset clause of 2025. This provides positive assurance for our employees and investors that we can continue investing into high growth biotechnology companies beyond 2025.   In addition, for SEIS investors, from April 2023 our SEIS fund can invest upto £250K in a company. This is […]
- [o2h Ventures Portfolio Companies Update](https://o2hventures.com/blog/o2h-ventures-portfolio-companies-update): In the post budget (S)EIS euphoria, we are excited to share some of the results from our recent survey from all of our 28 portfolio companies. The results are exciting given the size and longevity of our tax-efficient funds!  Our portfolio companies have together raised more than £230 million since their inception. Given the quanta we have invested in these companies, this demonstrates the interest that UK biotech companies generate globally. Startups iin their early stages have the ability to expand employment opportunities and add new jobs to the economy. We are pleased to report that our portfolio companies have […]
- [o2h Ventures qualifies as a FINALIST in the Growth Investor Awards 2022](https://o2hventures.com/blog/o2h-ventures-qualifies-as-a-finalist-in-the-growth-investor-awards-2022): Cambridge, UK: We are extremely excited to announce that o2h Ventures has been shortlisted as a finalist at the Growth Investor Awards 22 for the ‘ Best EIS Manager – Specialist’ category. The category acknowledges and celebrates outstanding investment managers in Enterprise Investment Schemes with a specialist focus on a particular area of underlying investments. The evaluation was based on assessing the success across business performance, investment inflows, impact on the investors, adviser relations, customer feedback, and overall impact. The focus of o2h Ventures has always been to seek out biotech therapeutic opportunities within the UK and then support these […]
- [o2h Ventures backed Neurofenix raises $7 Million to transform stroke and brain injury recovery](https://o2hventures.com/press-releases/o2h-ventures-backed-neurofenix-raises-7-million-to-transform-stroke-and-brain-injury-recovery): Health tech startup Neurofenix was founded to improve rehabilitation for neurological patients Over 75% of stroke, traumatic brain and spinal cord injury patients face long-term disabilities because of insufficient neurorehabilitation and a shortage of occupational therapists Once patients are discharged, they’re even less likely to complete home therapy programmes due to a lack of engagement, monitoring or support   Neurofenix’s patient-focused approach combines sensor-based technology and a telemedicine platform to personalise rehab and improve recovery and outcomes  Neurofenix has raised $7 million in funding in this round led by AlbionVC to build out the product team and invest in US expansion  […]
- [July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio](https://o2hventures.com/news/july-2022-o2h-ventures-fund-newsletter-deals-executed-in-alevin-therapeutics-neurofenix-five-alarm-bio): Amid the ongoing debate about who will be the next Prime Minister of the UK; it will be important that whoever eventually wins continues to invest in building the UK Biotech ecosystem. Reflecting back on the last month for o2h Ventures, we are pleased to announce the successful closing of the o2h human health SEIS Fund. We executed three deals in the last month with one investment in the SEIS Fund and two investments in the KI EIS Fund.  Industry Update: According to the latest report published by UK Business Angels Association published July 2022, there is a  knowledge gap […]
- [Funding boost for spin-out developing new medicines for life-threatening diseases](https://o2hventures.com/press-releases/investment-into-alevin-therapeutics): Cambridge, UK, 29 July 2022: A University of Nottingham spin-out company has received investment to further develop research into creating safe and effective medicines for patients with life-threatening diseases. o2h Ventures has announced SEIS and EIS investment, alongside co-investment from the University of Nottingham’s Invention Fund, into spin-out company Alevin Therapeutics to develop a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities. The discovery-stage compounds have broad therapeutic applications in areas of high unmet clinical need – fibrosis, kidney disease and cancer – with the most advanced asset being an inhaled drug for the treatment of […]
- [o2h Ventures makes an SEIS investment into CardiaTec](https://o2hventures.com/press-releases/seis-investment-into-cardiatec): Cambridge, UK, 06 July 2022: CardiaTec, an AI drug target discovery company specializing in cardiovascular disease, has secured a £1.4m pre-seed investment led by Laidlaw Scholars Ventures (LSV) and APEX Ventures with participation from Crista Galli Ventures, o2h Ventures and Cambridge Enterprise. Cardiovascular diseases have persisted as the world’s leading global cause of death since the 1980s. Yet, despite the rising number of deaths,  cardiovascular investment and therapeutic innovation are immensely dwarfed when compared to fields such as oncology and neurodegenerative diseases. New technologies must emerge to help close the gap. CardiaTec is developing a target discovery platform leveraging AI […]
- [o2h Ventures backed Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer](https://o2hventures.com/press-releases/spirea-raises-3m-to-develop-antibody-drug-conjugates-in-cancer): ● Investment co-led by Jonathan Milner and Cambridge Enterprise ● US-based R42 Group, ACF Investors, o2h Ventures, Syndicate Room and the Cambridge Angels investing ● Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours Cambridge, UK, 14 June 2022: Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of superior and differentiated ADCs in the […]
- [May 2022, o2h Ventures Fund Newsletter, SEIS fund close deadline June 30th 2022](https://o2hventures.com/news/funds-newsletter-may-2022): We hope that you are looking forward to a warm summer! We had a good closing of both the funds last month which also marked the end of tax year 2021-2022. o2h Ventures have stayed focused on building a strong pipeline of exciting early-stage biotech companies. We see strong deal flow at the Seed stage and the slight cooling of the markets has taken off some of the froth from the valuations which is not necessarily a bad thing when on the investing side!. Several of our portfolios are closing Series A funding as the companies have now had a […]
- [The "o2h human health KI EIS fund" makes an investment into Neurocentrx](https://o2hventures.com/press-releases/human-health-ki-eis-fund-investment-into-neurocentrx): Cambridge, UK, 12 May 2022: o2h Ventures is pleased to announce an EIS investment into Neurocentrx Pharma Ltd, a collaborative biotech company based in Edinburgh developing orally delivered drug products formulations of ketamine that are primarily aimed to treat mood disorders like Depression. Neurocentrx’s broader interests lie in psychiatric, mental health and mood disorders, neurodegenerative diseases and complex pain management in cancer and palliative care. Their focus is to provide existing approved drugs in new and improved formats for patients – through reformulation, reindication, clinical development and product in-licensing. Neurocentrx is currently commencing phase 1 development with one of their […]
- [o2h Ventures Deal Pipeline, KI EIS Fund closing on 5th April 2022](https://o2hventures.com/news/human-health-ki-eis-funds-closing): We write this note with a glimmer of hope that talks behind the scenes between Ukraine and Russia seem to be progressing. Markets have reacted positively to these talks whilst the bombing continues. In a post pandemic era, investors are now well versed in the impact that biotechnology can have all over the world with real products that can generate value for investors and patients. The pandemic did teach us how to bring new drugs to patients faster, lessons that the industry will no doubt pick-up and implement. We at o2h Ventures have stayed focused on building and supporting our […]
- [Investing in knowledge intensive EIS Fund by o2h Ventures](https://o2hventures.com/blog/investing-in-knowledge-intensive-eis-fund-by-o2h-ventures): “We asked tax expert Chris Lee, founder of Fiscability, to provide some further background around the advantages of investing into EIS investment in general, and of HMRC approved knowledge-intensive EIS funds in particular.” o2h Ventures launched the first HMRC approved ‘Human Health KI EIS Fund’ in October 2020. This focuses on investing into early-stage biotechnology companies in the United Kingdom. o2h Venture Funds have now invested into around 25 biotechnology companies, some of which have now progressed into the clinic which include Small Pharma, Exonate and Phoremost. Given that the o2h Ventures fund exclusively invests in Biotechnology it made sense to […]
- [The "o2h human health SEIS fund" makes an investment into Neucruit](https://o2hventures.com/press-releases/human-health-seis-fund-invests-into-neucruit): Cambridge, UK, 18 Feb 2022: o2h Ventures is pleased to announce a SEIS investment into Neucruit, a London based company that has developed an Intelligent lead generation software for clinical trial recruitment that helps sponsors and healthcare professionals reach thousands of potential participants in just one click. It is the first platform that allows teams to complete digital patient recruiting duties, obtain patient-specific information, get support, and keep patients engaged – all in one place. The technology aggregates real-time data from the over 25 million health-related conversations initiated online everyday to facilitate planning and recruitment in clinical trials. Less than […]
- [o2h Ventures makes a follow-on investment into Oxford Drug Design](https://o2hventures.com/news/human-health-ki-eis-fund-invests-into-oxford-drug-design): Cambridge, UK, 18 Feb 2022:  The o2h human health KI EIS Fund is pleased to announce a follow-on investment into Oxford Drug Design (ODD), an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods.  ODD are discovering new drugs with differentiated modes of action against challenging diseases with high unmet medical need. Based on a core competence platform in tRNA synthetase enzymes and distinctive AI/ML methods, their pipeline expansion is focused on oncology. Prior to this, o2h Ventures invested in ODD’s major funding round in July 2019 where ODD won major funding awards from CARB-X, the UK […]
- [o2h Ventures makes an investment into Xploro from “the o2h human health SEIS fund”](https://o2hventures.com/news/human-health-seis-fund-invests-into-xploro): Cambridge, UK, 16 Feb 2022: o2h Ventures is pleased to announce an SEIS investment into Xploro®, a Manchester based company using augmented reality, gameplay, and artificial intelligence to deliver health information to young patients.  Xploro reassures patients by clarifying what the upcoming procedure will accomplish, and assists in minimising procedural anxiety by enhancing health literacy and awareness about the treatment. Xploro has one of the highest ORCHA scores (Orcha seeks out the most popular digital health solutions and reviews them for compliance and best practice.) Artificial Intelligence’s growing influence and role in revolutionising the healthcare business cannot be overlooked while […]
- [o2h Ventures is hosting Christmas Special ChaiTime 'Jingle Chai' - Fireside Chat with Sir Mene Pangalos](https://o2hventures.com/news/fireside-chat-with-sir-mene-pangalos):   As the Christmas season fast approaches us, o2h Ventures is back with a Christmas special ChaiTime; ‘Jingle Chai’ this Thursday 16th December at 6.15 pm GMT (1.15 pm EST/11.45 pm IST). Adding to our series of ChaiTime webinars, we are pleased to announce that we have organized a Fireside chat with our special guest Sir Mene Pangalos. We are honored that Sir Mene Pangalos, Executive Vice-President, BioPharmaceuticals R&D Astrazeneca will join us for this Christmas special ‘Jingle Chai’ where we will gain some insights in the AZ vaccine development, research areas of focus and the role that AZ is […]
- [In4Derm raises £1.6m pre-Series A funding to support its growing pipeline of first-in-class anti-inflammatory and orphan disease therapeutics](https://o2hventures.com/press-releases/in4derm-raises-1-6m-pre-series-a-funding): Dundee, UK (2nd November 2021): In4Derm announces a £1.6m pre-Series A funding round to support the continued development and expansion of its pipeline of first-in-class anti-inflammatory and orphan indications therapeutics. In4Derm is a spin out from the world leading University of Dundee’s School of Life Sciences and has laboratory facilities in Dundee, Scotland. Following spin out and a seed round in 2020, In4Derm entered an option and licensing arrangement for its topical and oral BET inhibitor (BETi) programmes with Vyne Therapeutics in early 2021. The deal brings potential payments including upfronts and milestones of over $80m along with royalties. In […]
- [Interim Close: HMRC approved Human Health EIS Knowledge Intensive Fund](https://o2hventures.com/news/interim-close-human-health-ki-eis-fund-2021): We will soon close another round of successful investment in our flagship HMRC approved, Human Health EIS KI Fund. The final date to receive cleared funds is the 31st October 2021. Below is a flavour of some of the companies that you could be investing into. AlternOx – Biotech – Anti Fungal A spin-out of the University of Sussex focused on the exploitation of novel and proprietary inhibitors of the enzyme alternative oxidase (AOX) to treat a wide range of multi-drug and multi compound resistant species of fungi that now threaten human health and food security worldwide. In4Derm – Biotech – Inflammation […]
- [o2h Ventures “Human Health SEIS Fund” Invests into Sanome...](https://o2hventures.com/news/human-health-seis-fund-invests-into-sanome): Cambridge, UK, 28 Sept 2021: o2h Ventures is pleased to announce an investment into Sanome, a London-based biotech company combining biomarkers (health data points) into a human health passport that helps people understand and manage their health better. Sanome raised £2m as its first round of funding from a number of leading UK and European HealthTech specialist investors including o2h Ventures. Sanome is a digital health company that has developed a diagnostics innovation engine that combines biomarkers to produce medical-grade, at-home diagnostic products (IVDs) more efficiently and effectively. Most digital health, wearables, and consumer biotech tools have limited medical use […]
- [o2h Ventures Human Health Tax Efficient Investment Funds](https://o2hventures.com/news/september-2021-update): (Note: This newsletter has been approved as a financial promotion by o2h Ventures Limited) Thank you for subscribing earlier to our newsletter updates.  The o2h Ventures ‘Human Health’ funds make tax efficient EIS investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem; and we spur the creation of software and artificial intelligence that will change healthcare.  Please note this newsletter will cover the overall performance and companies in all our funds since inception and include both realised and […]
- [o2h Ventures portfolio company Small Pharma Successfully Completes Phase I Clinical Trial of DMT-assisted therapy](https://o2hventures.com/ventures/small-pharma-successfully-completes-phase-i-clinical-trial): Small Pharma’s DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers Dataset generated from Phase I enables the selection of the optimal dose of SPL026 to take forward into Phase IIa Small Pharma’s Phase IIa clinical trial to explore the effectiveness of SPL026 in combination with psychotherapy for the treatment of Major Depressive Disorder has been initiated LONDON, Sept. 21, 2021 (GLOBE NEWSWIRE) – Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase […]
- [o2h group is supporting the upcoming BiotechBikers' networking event in The UK](https://o2hventures.com/news/supporting-biotechbikers-networking-event-uk):   We are excited to be supporting the upcoming BiotechBikers’ networking event cycle ride in Cambridge, UK. BiotechBikers brings together “bike-minded” pharma professionals in a unique networking community based around guided group rides, virtual meetups and other social events. The event will take place on Saturday 18th September starting 8:15 am from the Mill SciTech Park where the o2h Group are shaping one of the region’s most exciting community of entrepreneurs in life-science, technology and green innovation. Find the Event agenda below : 08:15 – 09:00 Pre-ride refreshments and networking 09:00 – 12:15 Two social rides, a short and steady (~40km) […]
- [o2h Ventures backed Arecor enters into an exclusive formulation collaboration with Intas Pharmaceuticals](https://o2hventures.com/ventures/arecor-enters-into-exclusive-formulation-collaboration-with-intas-pharmaceuticals): Cambridge, UK, 07 September 2021– Arecor Therapeutics plc, the biopharmaceutical group which is advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation agreement with Intas Pharmaceuticals Ltd (“Intas”).  Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated product for Intas. The new product formulation supports improved usability for the patient compared to current marketed products and in particular facilitates home use outside of a healthcare environment. Intas will fund the development work and has the option to acquire the global rights to the new proprietary formulation and […]
- [o2h Ventures makes it to the finals in the EISA Awards 2021...](https://o2hventures.com/news/in-the-finals-eisa-awards-2021): We are delighted to share that o2h Ventures has been shortlisted as a finalist in the upcoming EISA Awards 2021 in the Best Newcomer category. The 2021 EISA Awards denote excellence in a number of EIS/SEIS fields and recognise the achievements of EIS/SEIS practitioners during the past year. The awards have a stellar judging panel again this year with a wide variety of experience from across the EIS and small business industry who independently assess entries and determine winners based on merit alone. o2h Ventures is the fund manager of the o2h Human Health Knowledge-Intensive EIS Fund which is the […]
- [o2h Ventures backed In4Derm enters into an exclusive license agreement with VYNE Therapeutics](https://o2hventures.com/news/in4derm-enters-into-an-exclusive-license-agreement-with-vyne-therapeutics):   VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high unmet needs VYNE expects to enter VYN201 and VYN202 into the clinic in 2022 BRIDGEWATER, N.J., August 12, 2021 — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has entered into an exclusive license agreement (the “License Agreement”) with In4Derm Limited (“In4Derm”), a spin-out of the University of Dundee’s School […]
- [o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics](https://o2hventures.com/news/invesment-into-bivictrix-therapeutics): Cambridge, UK, 05 August 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience.  BiVictriX is dedicated to applying a novel approach in developing safer and effective cancer therapies, by revolutionizing cancer therapy and making curative treatments available to all; By delivering a broad pipeline of proprietary, first-in-class Bi-Cygni® therapeutics to enable potentially higher dosing and more aggressive tumor eradication in patients, without causing harmful side effects. The company also announced that it will be listed on the AIM […]
- [Digital brain biomarker company Monument Therapeutics raises £2.6 million](https://o2hventures.com/news/monument-therapeutics-raises-2-6-million): Manchester, UK, June 28, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.  Monument Therapeutics has a pipeline of promising drug development programmes, with the most advanced two being for cognitive impairment in schizophrenia and […]
- [Seasonality -  Investing all year round using SEIS and EIS](https://o2hventures.com/blog/investing-all-year-round-using-seis-and-eis): Following the tax year end we need to dispel the misconception that S/EIS investing is seasonality driven and based around the end of the tax year. As we move into an era of rebuilding the economy, investing in innovative British businesses has never been more important. Successful S/EIS investing is down to good planning and not just timing and importantly access to exciting investment opportunities all year round. Let’s look at a couple of the discussion areas: Investor Considerations and Financial Planning EIS and SEIS are becoming increasingly more important as financial planning tools within an adviser’s offering as well […]
- [o2h Ventures backed Arecor Granted Key US Patent](https://o2hventures.com/news/arecor-granted-key-us-patent):   Cambridge, UK, May 2021: o2h Ventures are active investors in early stage biotech therapeutics & AI. We are pleased today to share the news that Arecor, a Cambridge, UK, based biotechnology company (‘Pre-Fund Investment’ portfolio company) has had it’s U.S. Utility Patent No. 10,925,965 B2 granted by the United States Patent and Trademark Office.  This patent contributes to the Company’s global patent portfolio, underpinning its ArestatTM technology platform. The patent claims proprietary formulation technology aimed at enabling stabilised multi-dose protein products, a desirable attribute which is challenging to achieve. The US is the key international market for biopharmaceuticals and […]
- [o2h Ventures backed Small Pharma Raises Cash to Fund Reverse Takeover on Toronto Stock Exchange](https://o2hventures.com/news/small-pharma-raises-cash-to-fund-reverse-takeover-on-toronto-stock-exchange):   Cambridge, UK, May 2021: o2h Ventures are excited to announce that Small Pharma backed by the fund managers “o2h human health EIS fund” has completed a fund raise of $58M CAD and listed on the Toronto Stock Exchange. Sunil Shah, CEO at o2h Ventures said: “This is a very exciting event for Small Pharma and they now have raised the funds required to see them through the next phase of the development of their drug.  Congratulations to Peter Rands and the team at Small Pharma for this tremendous event”.   Small Pharma will use the funds to accelerate the development […]
- [o2h Ventures backed In4Derm Announces a Strategic Partnership with a Nasdaq listed biotech with a >$200m Option License Agreement](https://o2hventures.com/news/o2h-ventures-backed-in4derm-signed-an-option-and-licensing-agreement): Cambridge, UK, May 2021: o2h Ventures are excited to announce that In4Derm, backed by the fund managers “o2h human health EIS fund” has signed an Option and Licensing Agreement based around its pipeline of first-in-class, selective BET inhibitors. The strategic partnership brings further financial and development support to In4Derm in addition to a novel pipeline for the partner. Sunil Shah, CEO at o2h Ventures said: “This early discovery stage collaboration will both provide the resources and speed up the time to provide novel drug therapeutics to patients. The first commercial deal for the company is a great platform for the […]
- [Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year](https://o2hventures.com/news/sunil-shah-wins-the-cambridge-independent-awards-as-ceo-of-the-year): Cambridge, UK, 16th April 2021 We are delighted to announce that Sunil Shah of o2h ventures has won the prestigious award at the Cambridge Independent Science and Technology Awards as CEO of the Year.  Sunil and his brother (co-founder) Prashant have been building the Anglo-India o2h Group together since 2003. They have built a scientifically driven ecosystem of ~350 people to support and invest into early stage therapeutic, AI driven biotech companies.  The o2h Group has research infrastructure and investments in Cambridge, UK and Ahmedabad, India with collaborations across three continents. In Cambridge UK, o2h Group has been developing the […]
- [University of Sussex and o2h Ventures Announce Creation and Investment in Stingray Bio, a Company for New Oncology Drugs Targeting the LMTK3 Kinase Pathway](https://o2hventures.com/news/university-of-sussex-and-o2h-ventures-announce-creation-and-investment-in-stingray-bio): April 2021, Cambridge, UK – o2h Ventures, a UK based fund manager through investment in its SEIS and EIS human health funds is excited to announce an investment into Stingray Bio Ltd, a new spin out from the University of Sussex supported by the Sussex Innovation Centre. Stingray Bio is developing new novel small molecule inhibitors of the LMTK3 kinase signaling pathway to treat breast and other cancers. Stingray’s drug target rationale has been extensively validated by its founders, Professors Georgios Giamas and John Spencer of the University of Sussex. Stingray Bio targets the neglected LMTK3 kinase signaling pathway: like […]
- [The o2h human health S/EIS flagship fund - Fully Deployed](https://o2hventures.com/news/the-o2h-human-health-s-eis-fund-fully-deployed): We are delighted to announce that the o2h human health S/EIS fund is now fully deployed with diversification into 18 companies. The mixed S/EIS fund has given investors access to some really exciting investment opportunities across biotech, therapeutics and AI.  As the UK biotech and life sciences industry is showcasing the best of UK innovation, at o2h we are privileged to be at the forefront of these investments. For full details of the portfolio please see our website https://o2hventures.com/portfolio At o2h we are continuing to support the industry with the launch of the first HMRC approved knowledge intensive fund which […]
- [o2h Ventures invests into SomaServe’s successful Series A funding round](https://o2hventures.com/news/o2h-ventures-invests-into-somaserves-successful-series-a-funding-round): Cambridge, UK, 31th March 2021 – SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed Series A funding of £2.1m. SomaServe has also secured further IP and global commercial rights to PolyNaut platform technology (the bionic nanoparticle) from UCLB. The company now has exclusive PolyNautâ rights in all indications. The o2h human health EIS Fund invested into Cambridge, UK based Somaserve Ltd in its seed funding round in July 2019. Investors at that time included Abcam and a small group of angels including some Cambridge Angels. New investors alongside […]
- [o2h Ventures invests in PhoreMost Series B financing](https://o2hventures.com/news/investment-into-phoremost-series-b-financing): Cambridge, UK, 23 March 2021: o2h Ventures is delighted to announce an investment into PhoreMost Ltd, a UK-based biopharmaceutical company dedicated to Drugging the Undruggable® for the benefit of humankind. o2h Ventures* have invested in each round since its launch in March 2015 when it invested alongside Cambridge University, Jonathan Milner and Amadeus. Investors for subsequent rounds include Astellas Venture Management, BGF, Morningside, Parkwalk, Trend Investment Group, and XtalPi.  PhoreMost Ltd today announced it has completed an oversubscribed £33m ($46m) Series B investment round. The funding will be used to progress PhoreMost’s preclinical ‘Allosteric PLK1’ collaboration with Sentinel Oncology into […]
- [Building Britain into a Scientific Superpower...](https://o2hventures.com/press-releases/building-britain-into-a-scientific-superpower): The ‘o2h Ventures Human Health Knowledge Intensive fund’ is the only HMRC approved fund in the world that is singularly focused on investing into British early stage biotech therapeutics. When Rishi Sunak, the Right Honorable Chancellor delivered his budget speech he referred to Britain’s aspiration to be a ‘Scientific Superpower’. At o2h Ventures we have reviewed and evaluated a significant number of innovative businesses over the last 2 years and we have made investments into around 35 companies*. We can concur that Britain has the potential to be a ‘Scientific Superpower’; we have world-class scientists and infrastructure along with strong […]
- [o2h Human Health EIS Fund leads an investment into Kuano, using quantum and AI to accelerate the development of new medicine.](https://o2hventures.com/news/o2h-ventures-human-health-eis-fund-leads-an-investment-into-kuano): London, UK, 25 Feb 2021: The o2h human health EIS Fund is pleased to announce an investment in Kuano, a London based company using quantum and AI to simulate  drug and virus interactions to identify drugs to shortcut the drug discovery process and improve the chances of success.  Kuano has identified four attractive drug targets with huge commercial benefit to demonstrate their technology platform and if successful these could be licensed to big pharma. Simultaneously they will seek collaborative deals with pharma and biotech to leverage their technology platform to support their on-going innovations.  o2h Ventures has a track record […]
- [o2h ventures backed Small Pharma receives approval for world’s first DMT for depression clinical trial](https://o2hventures.com/news/small-pharma-receives-approval-for-dmt-for-depression-clinical-trial): Small Pharma receives regulatory approval for clinical trial to explore DMT for depression, which it claims is the world’s first patient clinical trial of the psychedelic. London-based Small Pharma has been given the green light by UK regulators for a trial assessing the safety, and later efficacy, of N,N-dimethyltryptamine (DMT) in depression. The company believes that DMT can offer a shorter psychedelic therapy session, given that it “delivers a psychedelic experience in 20 minutes” according to CEO Peter Rand. Small Pharma’s Chief Medical & Scientific Officer Carol Routledge likened the high-dose psychedelic experience to “shaking up a snow globe, disrupting unhealthy patterns […]
- [o2h Ventures invests into the UCL spin out company SomaServe. ](https://o2hventures.com/news/investment-into-somaserve): The o2h human health EIS Fund, is excited to announce a follow-on investment into Cambridge, UK based Somaserve Ltd.  Somaserve is well positioned to collaborate with both biotechnology and pharmaceutical companies to explore its proprietary PolyNaut® Technology to improve the therapeutic viability of molecules. Somaserve is under-going an evaluation of its technology with one of the largest pharma companies in the world. It has also established a commercial partnership with AiM listed multi-billion  GBP Abcam to develop and commercialise its technology through its customer base.   Prior to this, o2h Ventures invested in its seed funding round in July 2019. Investors […]
- [Biotech investing… the UK is attracting attention](https://o2hventures.com/blog/biotech-investing-the-uk-is-attracting-attention): We are seeing death rates and cases decrease and vaccination distribution increases, but does this mean that we are at the tail end of the pandemic?  Well we all hope so; one of the trends that we have seen in these uncertain times is certain industries coming through this stronger, and biotech companies seem to have a tail wind.  The SPDR S&P Biotech ETF is making fresh highs; investors have been reading their old biology textbooks and realise the importance of science on both the economy and society. 2020 was a marquee year for biotech fundraising. The total capital raised by […]
- [Biotech and digital therapeutics…a great opportunity](https://o2hventures.com/blog/biotech-and-digital-therapeutics-a-great-opportunity): We live in a world where technology is in a constant state of evolution and nowhere is this more evident than innovative biotechnology and digital therapeutics. What is biotechnology? At its simplest, biotechnology is technology based on biology – biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet. In medicine, biotechnology companies focus on novel drug development and clinical research aimed at treating diseases and medical conditions. This may sound very broad, but it is important to break it down and look at some of the exciting […]
- [Investing in Therapeutics and Biotech Innovation](https://o2hventures.com/blog/investing-in-therapeutics-and-biotech-innovation): Knowledge intensive investments focus primarily on innovation. The UK is perfectly placed to build on its high quality academic and scientific foundations to generate start-up companies with fantastic scientific ideas that will be developed into high value assets. o2h ventures have been privileged to be able to invest in a number of these fledgling businesses. Innovations come in many guises. Our focus has been in therapeutics, machine learning/artificial intelligence (ML/AI) and to a lesser extent digital technologies/therapeutics. Here we take a brief look at some of the investments our flagship human health EIS fund has invested in over the last […]
- [o2h ventures – making waves in knowledge intensive and SEIS investing](https://o2hventures.com/news/o2h-ventures-making-waves-in-ki-and-seis-investing): Last month we announced the launch of the o2h human health EIS knowledge intensive fund, the first knowledge intensive fund approved by HMRC. At o2h ventures we invest into biotech therapeutics and are in an exciting position to meet the criteria for knowledge intensive investing.  We seek to nurture seed stage companies through their lifecycle working alongside the portfolio with a view to generate returns (financial, social and ethical) for investors.   Within the ‘biotech therapeutic’ space the areas that the fund invests into are: traditional therapeutic drug opportunities; technologies that enable drug discovery with an emphasis on Artificial Intelligence (AI) […]
- [Knowledge intensive investing… a new investment era](https://o2hventures.com/news/knowledge-intensive-investing-a-new-investment-era):   The only certain outcome of the COVID-19 pandemic is to vindicate the value of investing in  biomedicine. Vaccines will be made, treatments will be found, and the social and financial value of medical scientists and innovation will be proven again. Biotechnology and Healthcare are proving to be amongst the top performing investment sectors over the last decade, particularly at a time when their importance has never been more clear.  In April 2020 the UK government acknowledged the importance of knowledge intensive companies and more importantly the importance of funding them. The introduction of Knowledge Intensive EIS funds allows UK […]
- [o2h ventures leads the funding into Cambridge University Biotech Spinout Spirea](https://o2hventures.com/news/leads-the-funding-into-spirea): The o2h human health EIS Fund, is excited to announce an investment into Spirea, a University of Cambridge Biotechnology spin out that is developing the next generation of game changing antibody drug conjugates (ADC) to transform cancer treatment and drastically improve the lives of patients. Spirea has developed a proprietary platform technology, ShieldLink, that may lead to novel ADCs with enhanced ability to treat patients safely and effectively. Sunil Shah, CEO at o2h ventures, said: “There is a significant interest in ADC’s, as seen by Merck’s recent $2.75B VelosBio acquisition for their ROR1 antibody drug conjugate. We believe that this […]
- [Q&A with Angel Investor Sunil Shah | The Sunday Times](https://o2hventures.com/news/qa-with-angel-investor-sunil-shah-the-sunday-times): Sunil Shah, CEO of o2h ventures who recently won The Angel Investor of the Year by UKBAA was interviewed by Peter Evans, Enterprise Editor of The Sunday Times. The Q&A session was themed around Biotech Investing in the UK in which Sunil Shah has played an instrumental role since many years both as an active angel investor and a mentor. He shared his experience and future thoughts on the potential of Biotech and AI in the UK in the light of the recently launched o2h therapeutics and AI EIS fund. To read the full article, please click here- Q&A with Sunil Shah […]
- [o2h ventures leads investment round into In4Derm, a University of Dundee spinout...](https://o2hventures.com/news/o2h-ventures-leads-investment-round-into-in4derm): Cambridge, UK,  2020: The o2h human health EIS Fund is pleased to lead an investment into In4Derm, an innovative drug discovery company that is developing next generation topical and oral therapies for widespread inflammatory conditions such as eczema and rheumatoid arthritis. Syndicating with o2h ventures are Meltwind and Wren to complete a first investment in In4Derm. A spin out from Dundee University, the team has been recognised as Scotland’s top spin out opportunity for 2020 having won the top prize in the 2019 Converge Challenge competition.   The seed investment from o2h ventures will be used to complete lead optimisation for […]
- [o2h ventures launches the first HMRC approved knowledge intensive EIS fund focused on UK biotech therapeutics & AI](https://o2hventures.com/news/knowledge-intensive-eis-fund-launch): o2h ventures is delighted to announce the launch of their HMRC approved knowledge intensive EIS fund, focusing on supporting the expansion of UK research and development in biotech therapeutics and AI.   To support the Government’s aim to strengthen and grow UK innovation, which were known to be capital and research intensive, the EIS knowledge intensive fund has been launched to pledge support to companies working in this space, providing them access to capital to develop their early novel ideas. Knowledge intensive investing offers investors an opportunity to take advantage of the predictability of the tax year, from which they are […]
- [o2h ventures makes an investment into digital therapeutic Cortirio...](https://o2hventures.com/news/o2h-ventures-invests-in-cortirio): Cambridge, UK, October 2020: The o2h human health EIS Fund, is pleased to lead an investment into digital therapeutic Cortirio Limited alongside University of Surrey and KQ Labs. Traumatic brain injury is the leading cause of death and disability among the under 45s and a growing problem for our aging population as falls become more prevalent. Cortirio’s portable scanners can be used at the point of care to enable the early treatment of traumatic brain injuries. By saving time, this technology will save brain function and avert disability and death Sunil Shah, CEO at o2h Ventures said: “We are very […]
- [o2h ventures makes it to the finals in the EISA awards 2020](https://o2hventures.com/news/o2h-ventures-finalists-eisa-awards-2020):   We are excited to announce that o2h Ventures has been shortlisted as a finalist in the upcoming EISA 2020 Awards in the Best Newcomer category. The category champions new entrants to the S/EIS market who are already making a significant impact. Investing in seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies, our human health EIS Fund is supporting innovation across UK life sciences. We have a track record of nurturing and investing into emerging life sciences and technology start-ups. The fund is in a unique position to offer investors access to innovative […]

## Pages

- [Thank You](https://o2hventures.com/download-information-memorandum-form-ki-eis-growth/seven-sisters-ki-eis-thankyou): Dear  , This is a high-risk investment. How would you feel if you lost the money you’re about to invest? Take 2 mins to learn more
- [Thank  you investor seven sisters ki eis growth](https://o2hventures.com/thank-you-investor-seven-sisters-ki-eis-growth): Dear  , This is a high-risk investment. How would you feel if you lost the money you’re about to invest? Take 2 mins to learn more
- [Step 2](https://o2hventures.com/download-information-memorandum-form-ki-eis-growth/step-2)
- [Download Information Memorandum Form - Seven Sisters KI EIS Growth](https://o2hventures.com/download-information-memorandum-form-ki-eis-growth)
- [events](https://o2hventures.com/events)
- [Event registration contact form](https://o2hventures.com/event-registration-contact-form)
- [What is Knowledge Intensive EIS fund ?](https://o2hventures.com/knowledge-intensive-eis-fund)
- [Thank  you investor SEIS](https://o2hventures.com/thank-you-investor-seis): Dear  , This is a high-risk investment. How would you feel if you lost the money you’re about to invest? Take 2 mins to learn more
- [Thank you](https://o2hventures.com/download-information-memorandum/ki-eis-thank-you): Dear  , This is a high-risk investment. How would you feel if you lost the money you’re about to invest? Take 2 mins to learn more
- [step 2](https://o2hventures.com/download-information-memorandum/step-2)
- [step-2](https://o2hventures.com/download-information-memorandum-seis/step-2)
- [General settings](https://o2hventures.com/general-settings)
- [Thank you](https://o2hventures.com/download-hardman-co-report/thank-you): In case of queries, please reach out to us on invest@o2h.com
- [Download o2hventures Hardman & Co report](https://o2hventures.com/download-hardman-co-report)
- [Thank you - Summary Memorandum KI EIS](https://o2hventures.com/download-summary-doc-for-ki-eis/thank-you-summary-memorandum-ki-eis): In case if you have any queries, please do not hesitate to get in touch with us at invest@o2h.com
- [Thank you - Summary Memorandum SEIS](https://o2hventures.com/download-summary-doc-for-seis/thank-you-summary-memorandum-seis): In case if you have any queries, please do not hesitate to get in touch with us at invest@o2h.com
- [Download Summary Doc for KI-EIS](https://o2hventures.com/download-summary-doc-for-ki-eis)
- [Download Summary Doc for seis](https://o2hventures.com/download-summary-doc-for-seis)
- [Download Information Memorandum For SEIS](https://o2hventures.com/download-information-memorandum-seis)
- [Thank you](https://o2hventures.com/download-information-memorandum-seis/thank-you): Dear  , This is a high-risk investment.How would you feel if you lost the money you’re about to invest? Take 2 mins to learn more
- [the o2h human health funds](https://o2hventures.com/funds): Innovation in UK lifesciences & technology
- [Portfolio](https://o2hventures.com/portfolio)
- [Preview investor](https://o2hventures.com/preview-investor)
- [Congratulations!](https://o2hventures.com/top-up-successfull): Please include your Reference Number and Access Number when transferring Funds Account Number 90086428 Account Name O2H VENTURES CLIENT ACC Sort Code 20-17-68 Please include your Reference Number as well as Firstname and Lastname Initials when transferring Funds or you can pay by cheque, please write your Reference Number as well as Firstname and Lastname Initials on the reverse. Payable to O2H VENTURES CLIENT ACCOUNT Post to o2h Ventures Ltd Hauxton House, The Mill SciTech Park, Mill Lane, Cambridge CB22 5HX
- [Get in touch](https://o2hventures.com/contact/get-in-touch): powered by Typeform
- [Download Information Memorandum Form - KI EIS](https://o2hventures.com/download-information-memorandum)
- [Portfolio Diversification](https://o2hventures.com/portfolio-diversification)
- [Thank you](https://o2hventures.com/topup-thank-you): Please transfer your top-up amount via an online bank transfer to Account Number 90086428 Account Name O2H VENTURES CLIENT ACC Sort Code 20-17-68 Please include your Reference Number as well as Firstname and Lastname Initials when transferring Funds or you can pay by cheque, please write your Reference Number as well as Firstname and Lastname Initials on the reverse. Payable to O2H VENTURES CLIENT ACCOUNT Post to o2h Ventures Ltd Hauxton House, The Mill SciTech Park, Mill Lane, Cambridge CB22 5HX
- [Thank  you investor ki eis](https://o2hventures.com/thank-you-investor-ki-eis): Dear  , This is a high-risk investment. How would you feel if you lost the money you’re about to invest? Take 2 mins to learn more
- [Bank Details to Transfer Funds](https://o2hventures.com/verification-success): Please include your Reference Number and Access Number when transferring Funds Account Number 90086428 Account Name O2H VENTURES CLIENT ACC Sort Code 20-17-68 Please include your Reference Number as well as Firstname and Lastname Initials when transferring Funds or you can pay by cheque, please write your Reference Number as well as Firstname and Lastname Initials on the reverse. Payable to O2H VENTURES CLIENT ACCOUNT Post to o2h Ventures Ltd Hauxton House, The Mill SciTech Park, Mill Lane, Cambridge CB22 5HX
- [Top-up your Subscription](https://o2hventures.com/top-up-your-subscription): Enter the amount below to top-up your Subscription into the Fund.
- [redirect](https://o2hventures.com/redirect)
- [Investor login](https://o2hventures.com/investor-login)
- [Invest verification](https://o2hventures.com/invest-verification)
- [Register with us](https://o2hventures.com/register-with-us)
- [Thank you](https://o2hventures.com/contact/thank-you): We have received your message and will get back to you promptly.
- [Press releases](https://o2hventures.com/press-releases)
- [Media Coverage](https://o2hventures.com/media-coverage)
- [event](https://o2hventures.com/event)
- [news](https://o2hventures.com/news)
- [Reset password](https://o2hventures.com/reset-password): [ultimatemember_password]
- [Account](https://o2hventures.com/account): [ultimatemember_account]
- [Logout](https://o2hventures.com/logout)
- [Members](https://o2hventures.com/members)
- [Register](https://o2hventures.com/register)
- [Login](https://o2hventures.com/login)
- [User](https://o2hventures.com/user)
- [Terms & Conditions](https://o2hventures.com/terms-conditions): themrs
- [Privacy Policy](https://o2hventures.com/privacy-policy): This policy covers o2h ventures Ltd and affiliated entities. Introduction At o2h ventures we take your privacy seriously and we are committed to protecting Personal Data (information) that we receive from you. This Privacy Policy explains our policies and practices regarding its processing of your Personal Data and explains your privacy rights under applicable privacy and security laws. We notify you of this under the General Data Protection Regulation. ​We review our privacy practices on an ongoing basis, so we may change this Privacy Policy from time to time. If such changes include any significant, material changes, we will provide […]
- [FAQs](https://o2hventures.com/faqs): FAQs FAQs
- [Strategy](https://o2hventures.com/strategy): Strategy
- [Blog](https://o2hventures.com/blog): blog
- [Contact](https://o2hventures.com/contact): Contact
- [Documents](https://o2hventures.com/documents)
- [Team](https://o2hventures.com/team): this is rhe tem page
- [About](https://o2hventures.com/about): a passion for investing we have a track record of nurturing and investing in emerging life science and tech companies The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences amongst others which has led to higher potential exit valuations. The fund will help widen the community of investors that will help expand early stage research in the UK. The o2h ventures team are leaders in the biotech community and have been actively involved as […]
- [homepage](https://o2hventures.com/)
- [Sample Page](https://o2hventures.com/sample-page): This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I’m a bike messenger by day, aspiring actor by night, and this is my website. I live in Los Angeles, have a great dog named Jack, and I like piña coladas. (And gettin’ caught in the rain.) …or something like this: The XYZ Doohickey Company was founded in 1971, […]


[comment]: # (Generated by Hostinger Tools Plugin)